GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...
GSK is the fifth company to leave BIO in roughly a year, a group that includes Pfizer and UCB. The departures coincided ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
UK pharma group posts ‘statistically significant’ trial results for treatment combined with Blenrep pulled in 2022 ...
GSK is the fifth company to leave BIO in roughly a year, a group that includes Pfizer (PFE). The departures coincided with a drop in lobbying spending from the group and other challenges, STAT ...
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
GSK Pharmaceuticals India focuses on affordable general medicine access amidst premiumisation trend, discussed by managing ...
Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...
GlobalData on MSN8d
GSK’s RSV vaccine approved in Canada for adults aged 50 to 59GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback